Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils.

Ekmark-Lewén, S.; Gumucio, A.; Fälting, J.; Molisak, A.; Lannfelt, L.; Nordström, E.; Kahle, P. J.; Ingelsson, M.; Lindström, V.; Bergström, J.; Aniszewska, A.; Möller, C.

doi:10.1016/j.nbas.2023.100086

Journal Article

DZNE-2023-00784

Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils.

Ekmark-Lewén, S. ; Aniszewska, A. ; Molisak, A. ; Gumucio, A. ; Lindström, V. ; Kahle, P. J.DZNE* ; Nordström, E. ; Möller, C. ; Fälting, J. ; Lannfelt, L. ; Bergström, J. ; Ingelsson, M.

2023
Elsevier Amsterdam

Aging brain 4, 100086 (2023) [10.1016/j.nbas.2023.100086]

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.nbas.2023.100086

Abstract: Immunotherapy against alpha-synuclein (α-syn) is a promising novel treatment strategy for Parkinson's disease (PD) and related α-synucleinopathies. We have previously shown that systemic treatment with the monoclonal oligomer/protofibril-selective antibody mAb47 targeting cytotoxic α-syn leads to reduced central nervous system levels of such species as well as an indication of reduced late-stage symptoms in aged (Thy-1)-h[A30P] α-syn transgenic mice. Here, we performed an early-onset long-term treatment study with this antibody to evaluate effects on brain pathology and behavioral outcomes in the same mouse model. Compared to the placebo group, the treatment strongly reduced phosphorylated α-syn (pS129 α-syn) pathology in the upper brain stem. Moreover, a preserved recognition memory and risk assessment behavior could be seen in antibody-treated mice at six months of age, even although these effects were no longer significant at eleven months of age. Importantly, no evidence of inflammatory responses or other potential toxic effects was seen with the treatment. Taken together, this study supports the strategy to target α-syn oligomers/protofibrils with monoclonal antibodies to counteract early symptoms and slow down the progression of PD and other α-synucleinopathies.

Keyword(s): Alpha-synuclein transgenic mice ; Behavioral outcome ; Immunotherapy ; Oligomer/protofibril-selective antibody ; Oligomers